Recursion Pharmaceuticals(NASDAQ) RXRX

Recursion Pharmaceuticals, Inc. helps scientists find new disease treatments. It uses artificial intelligence to study biological data at high speeds. This process makes it easier to identify medicines for patients.

Building a New Medicine Cabinet

• REC-4881: Clinical drug candidate designed to treat Familial Adenomatous Polyposis; targets growths in the colon.
• Strategic Partnerships: Research efforts with firms like Genentech and Sanofi to discover new drug targets.
• REC-7735: Oncology candidate built to target specific mutations in solid tumors while reducing side effects.
• Recursion OS: Software and laboratory system used to generate biological data and design treatments.

Partners and Recent Progress

• Genentech advanced its first neuroscience target into an early discovery program after validating biological maps in 2026.
• Sanofi and the company progressed multiple molecules for immune and cancer treatments during the 12 months before June 30, 2026.
• The company appointed a new Chief AI Officer and a Senior Vice President of Drug Design in 2026.
• Recursion completed a $500 million stock offering in 2025 to fund its ongoing research and clinical trials.

How Tech Finds Targets

The company uses an AI-native system that integrates biological data generation with automated chemical synthesis. Its platform uses data sets from over one trillion cells to create maps that identify how diseases behave.

By the Numbers

• Total revenue was $7.7 million in the three months ended June 30, 2026, down 60% year over year.
• Net loss was $131.0 million in the three months ended June 30, 2026, down 24% year over year.
• Research and development expense was $177.5 million for the six months ended June 30, 2026, down 31% year over year.
• Cash and cash equivalents totaled $556.8 million as of June 30, 2026.
• The accumulated deficit reached $2.3 billion as of June 30, 2026.

The Evolution of Discovery

Recursion has shifted from a pure research firm to a clinical-stage business with multiple drug candidates in human testing. Its focus on combining artificial intelligence with automated laboratories aims to make medicine development more efficient.